by Daniel Schwartz | Sep 25, 2023 | Guidance for Patients, PHSP
Access to Care Reducing the Cost of Pharmaceuticals in Canada Canada is well-known for its universal healthcare system, which provides all citizens and permanent residents with access to medically necessary hospital and physician services without direct charges at the...
by Daniel Schwartz | Dec 14, 2022 | Guidance for Patients
CLINICAL TRIALS TIPS for STARTING AN SGLT2 inhibitor SGLT2i inhibitors (eg empagliflozin, dapagliflozin, canagliflozin) have a phenomenal evidence base and have been shown to be beneficial in diabetes, heart disease (particularly heart failure) and kidney disease....
by Daniel Schwartz | Dec 10, 2022 | Healthcare IT
HEALTHCARE IT 10 Opportunities to increase access to physicians through IT efficiencies In Canada (and elsewhere) we are facing unprecedented barriers in accessing physicians (both primary care & specialty care) & other healthcare providers. Many barriers...
by Daniel Schwartz | Nov 28, 2022 | Clinical Trials, Health Policy
CLINICAL TRIALS Should patients with diabetes, CKD and proteinuria despite RAASi & SGLT2i be considered for add-on therapy with finerenone (triple therapy)? A recent Twitter thread: As a Canadian nephrologist, relevant & active national debate in light of...
by Daniel Schwartz | Nov 27, 2022 | Clinical Trials
CLINICAL TRIALS Most impactful clinical trials: slowing progression of chronic kidney disease This is a highly subjective list, but these trials have been included as they have had a meaningful impact on guidelines, patients and clinicians at a global scale. 1. IDNT:...
Recent Comments